问题 › 我们是否应该收购竞争对手？ › HealthTech & Digital Health
收购失败更多是因为对风险合同与归属结果的对齐问题，而非价格本身。维持不匹配的参与率和客户流失所带来的成本，是最容易被低估的数字。 数字健康公司面对的这个问题版本与通用版本不同。结果风险的签约速度快于公司判断自身能否承担的速度——12个月的衡量窗口对上11个月的销售周期。因此，忽略风险收入分成的答案会出错。分析必须从参与率和毛利率出发，而非从收入出发。
收购失败更多是因为对风险合同与归属结果的对齐问题，而非价格本身。维持不匹配的参与率和客户流失所带来的成本，是最容易被低估的数字。 数字健康公司面对的这个问题版本与通用版本不同。结果风险的签约速度快于公司判断自身能否承担的速度——12个月的衡量窗口对上11个月的销售周期。因此，忽略风险收入分成的答案会出错。分析必须从参与率和毛利率出发，而非从收入出发。
收购竞争对手的理由通常建立在合并已注册成员以提升风险收入分成上，而这是最不可靠且到账最慢的一类收益。毛利率改善更可预测，且真实数字往往小于模型假设。
决定多数结果的数字是整合成本——对齐PMPM衡量窗口、核对归属结果，以及一年或更长时间内管理层注意力从现有客户身上转移。这项成本常被省略，因为难以估算且不出现在任何一方的账面上。
严谨版本会先问：具体能获得什么，是无法通过其他更低成本方式构建或购买的？如果风险收入分成协同完全无法实现，业务会变成什么样子。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 理由依赖于合并双方已注册成员的风险收入分成
✓ 提到整合，但未对参与率对齐和客户流失成本建模
✓ 收购部分动机来自核心业务的结果风险签约停滞
通常会让情况更糟的做法。 以风险收入分成协同为基础进行交易承保，而这类协同通常到账晚、规模小于模型，或根本无法实现。
It is for you if you run or finance a digital health company and the rationale leans on cross-selling to each other's customers. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Convert 2.9M contracted lives into Medicare Advantage outcomes contracts using existing payer integrations and outcomes proof points.
The leak it closes. Prevents value leakage to in-house payer solutions by demonstrating superior 12-month cohort outcomes data
The assumption it rests on. At least 4 of 34 existing health plans will sign MA outcomes contracts within 24 months — the engine put the probability at 0.75.
| Investment required | $1.8-2.4M total over 24 months |
| Expected return | 250-580% over 36 months on $62M base revenue |
| Revenue, year 1 | $2-4M incremental ARR (2-3 MA contracts) |
| Revenue, year 2 | $6-14M incremental ARR (4-7 MA contracts) |
| Revenue, year 3 | $12-25M incremental ARR (8-12 MA contracts) |
| Exit criteria | Abandon if fewer than 2 MA contracts signed by month 18 OR if engagement rate in MA pilot cohort falls below 30% OR if NCQA certification denied |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
估值两次：一次按独立价值，一次按它对你具体价值。两者差额是能支付且仍创造价值的最高上限，通常比预期更窄。
成本协同可靠得多。它们在你控制范围内且可安排时间表。收入协同取决于客户是否按模型行事，而这是最常出错的假设。
整合消耗的管理注意力超出预算，导致两家企业在交易本应回本的期间内均表现不佳。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית